# Psoriasis: Treatment and Pathogenesis

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the reciprocal developmental pathways for the generation of pathogenic effector TH17 cells and regulatory T cells, particularly in the context of autoimmune inflammation, interleukin-23, psoriasis, and the role of cytokines such as TGF-ß. It also explores the differentiation, cytokine profile, and function of human interleukin 17–producing helper T cells. |
| Domain | Life Sciences |
| Field | Immunology and Microbiology |
| OpenAlex ID | t10469 |
| Works | 566 |

## Topic papers all

Showing 15 of 566.

- [Classification criteria for psoriatic arthritis: Development of new criteria from a large international study](https://scholariq.org/papers/classification-criteria-for-psoriatic-arthritis-development-of-new-criteria-from/)
- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens](https://scholariq.org/papers/interleukin-22-mediates-early-host-defense-against-attaching-and-effacing/)
- [Risk of Myocardial Infarction in Patients With Psoriasis](https://scholariq.org/papers/risk-of-myocardial-infarction-in-patients-with-psoriasis/)
- [Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)](https://scholariq.org/papers/efficacy-and-safety-of-ustekinumab-a-human-interleukin-12-23-monoclonal-antibody/)
- [Phenotypic and functional features of human Th17 cells](https://scholariq.org/papers/phenotypic-and-functional-features-of-human-th17-cells/)
- [Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis](https://scholariq.org/papers/interleukin-22-a-th17-cytokine-mediates-il-23-induced-dermal-inflammation-and/)
- [The Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation](https://scholariq.org/papers/the-biological-functions-of-t-helper-17-cell-effector-cytokines-in-inflammation/)
- [Psoriatic arthritis: epidemiology, clinical features, course, and outcome](https://scholariq.org/papers/psoriatic-arthritis-epidemiology-clinical-features-course-and-outcome/)
- [Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial](https://scholariq.org/papers/secukinumab-a-human-anti-il-17a-monoclonal-antibody-for-moderate-to-severe-crohn/)
- [Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/dupilumab-treatment-in-adults-with-moderate-to-severe-atopic-dermatitis/)
- [Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways](https://scholariq.org/papers/genome-wide-scan-reveals-association-of-psoriasis-with-il-23-and-nf-b-pathways/)
- [Psoriatic Arthritis](https://scholariq.org/papers/psoriatic-arthritis/)
- [Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)](https://scholariq.org/papers/efficacy-and-safety-of-ustekinumab-a-human-interleukin-12-23-monoclonal-antibody-2/)
- [National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study](https://scholariq.org/papers/national-regional-and-worldwide-epidemiology-of-psoriasis-systematic-analysis/)

## Topic primary papers

Showing 15 of 263.

- [Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens](https://scholariq.org/papers/interleukin-22-mediates-early-host-defense-against-attaching-and-effacing/)
- [Risk of Myocardial Infarction in Patients With Psoriasis](https://scholariq.org/papers/risk-of-myocardial-infarction-in-patients-with-psoriasis/)
- [Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)](https://scholariq.org/papers/efficacy-and-safety-of-ustekinumab-a-human-interleukin-12-23-monoclonal-antibody/)
- [Phenotypic and functional features of human Th17 cells](https://scholariq.org/papers/phenotypic-and-functional-features-of-human-th17-cells/)
- [Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis](https://scholariq.org/papers/interleukin-22-a-th17-cytokine-mediates-il-23-induced-dermal-inflammation-and/)
- [The Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation](https://scholariq.org/papers/the-biological-functions-of-t-helper-17-cell-effector-cytokines-in-inflammation/)
- [Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways](https://scholariq.org/papers/genome-wide-scan-reveals-association-of-psoriasis-with-il-23-and-nf-b-pathways/)
- [Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)](https://scholariq.org/papers/efficacy-and-safety-of-ustekinumab-a-human-interleukin-12-23-monoclonal-antibody-2/)
- [National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study](https://scholariq.org/papers/national-regional-and-worldwide-epidemiology-of-psoriasis-systematic-analysis/)
- [Psoriasis and comorbid diseases](https://scholariq.org/papers/psoriasis-and-comorbid-diseases/)
- [A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1](https://scholariq.org/papers/a-genome-wide-association-study-identifies-new-psoriasis-susceptibility-loci-and/)
- [Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity](https://scholariq.org/papers/identification-of-15-new-psoriasis-susceptibility-loci-highlights-the-role-of/)
- [Prevalence of cardiovascular risk factors in patients with psoriasis](https://scholariq.org/papers/prevalence-of-cardiovascular-risk-factors-in-patients-with-psoriasis/)
- [Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics](https://scholariq.org/papers/joint-aad-npf-guidelines-of-care-for-the-management-and-treatment-of-psoriasis/)
- [Psoriasis](https://scholariq.org/papers/psoriasis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.